Per Seeking Alpha transcript of today's VRTX CC, it appears VRTX management said during Q&A that the results in the 200mg PK studies of VX-135 compared favorably with the results seen for sofosbuvir at 400mg. Is that not a fair statement?
I'm not sure what was discussed on the call today. A hold has been placed on the VX-135 200mg dose by the FDA. The 200mg dose may relate to European studies.
Market Data 
Markets 
AI
